3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Stomach Neoplasms
5
Rectal Neoplasms
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Ovarian Neoplasms
3
Neoplasms
3
Carcinoma, Hepatocellular
3
Breast Neoplasms
3
Uterine Cervical Neoplasms
2
Small Cell Lung Carcinoma
2
Sarcoma
2
Pancreatic Neoplasms
2
Melanoma
2
Lung Neoplasms
2
Esophageal Squamous Cell Carcinoma
2
Colorectal Neoplasms
2
Sarcoma, Ewing
1
SCLC
1
Retinoblastoma
1
Osteosarcoma
1
Oligometastatic Disease
1
Neoplasms, Germ Cell and Embryonal
1
Nasopharyngeal Carcinoma
1
NSCLC
1
Mouth Neoplasms
1
Lymphoma, Follicular
1
Lymphoma
1
Locally Advanced Resectable Rectal Cancer
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Glioblastoma
1
Interventions
Gemcitabine
4
Cisplatin
2
vinflunine
1
valrubicin
1
pembrolizumab
1
enfortumab vedotin
1
cabazitaxel
1
XRP6258
1
Rogaratinib
1
Oncolytic Virotherapy
1
Mitomycin
1
Interferons
1
Drug Therapy
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Carcinoma, Transitional Cell
×
Drug Therapy
×
Clear all
NCT03410693
2022-09-28
FORT-1
Bayer
Phase 2/3
Completed
175 enrolled
19 charts